8 known cases. View patent page →
Jazz asserted seven Xyrem patents, including the '275 patent; Amneal's answer included Count VII: Infringement of the '275 Patent. Consolidated into the D.N.J. Xyrem ANDA proceedings and ultimately resolved by settlement.
DrugPatentWatch lists 8,324,275 as asserted in Jazz Pharmaceuticals v. Roxane Laboratories; the case was resolved via the April 2017 Jazz–Roxane settlement.
The '275 patent appears in the list of patents-in-suit recited in the consolidated D.N.J. Watson pleadings; resolved by settlement. Consolidated with 14-6151 and 15-187.
Antitrust case citing the '275 patent as part of an alleged Orange Book/patent-thicket scheme; terminated Apr. 15, 2021 in D. Minn.
Antitrust case citing the '275 patent; terminated Jul. 15, 2020 by early dismissal and later refiled/consolidated in N.D. Cal.
Class action antitrust case citing the '275 patent as part of an alleged Orange Book scheme; consolidated in the N.D. Cal. Xyrem antitrust proceeding before Judge Seeborg.
Antitrust case citing the '275 patent; Jazz defendants were dismissed with plaintiffs' consent by order around Oct. 1, 2025.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.